Location History:
- Blemblens, CH (2020)
- Bremblens, CH (2019 - 2022)
Company Filing History:
Years Active: 2019-2022
Title: Bruno Correia: Innovator in Protein and Lipid Research
Introduction
Bruno Correia is an esteemed inventor based in Blemblens, Switzerland. His groundbreaking work has led to the development of three significant patents, cementing his reputation within the realms of protein interaction and lipid binding research. At The Scripps Research Institute, he has dedicated his efforts to advancing the understanding of protein-ligand interactions, which is crucial for drug development.
Latest Patents
Bruno Correia holds three notable patents, among which his latest contributions are particularly significant. The first patent, "Photoreactive ligands and uses thereof," discloses methods for identifying proteins that interact with small molecule ligands. This innovation includes compositions that aid in profiling druggable proteins, offering an essential tool for future drug discovery.
The second patent, titled "Lipid probes and uses thereof," presents methods, compositions, and assays for identifying lipid binding proteins as potential drug targets. This invention encompasses tools for mapping ligand binding sites on lipid binding proteins and generating drug-lipid binding protein profiles, thereby enhancing high-throughput drug screening methods.
Career Highlights
Throughout his career, Bruno Correia has gained extensive knowledge and expertise in the fields of biochemistry and pharmacology. His role at The Scripps Research Institute has provided him with opportunities to conduct cutting-edge research, contributing significantly to the scientific community. His innovative approaches in ligand and protein interactions showcase his commitment to advancing medical science.
Collaborations
Bruno has collaborated with notable scientists such as Benjamin F. Cravatt and Micah J. Niphakis. These collaborations have fostered a productive environment for innovation, allowing for the exchange of ideas and the collective pursuit of groundbreaking research. Their combined expertise has led to advancements that may transform current understanding and practices within the field.
Conclusion
In summary, Bruno Correia is a distinguished inventor whose contributions to the understanding of protein and lipid interactions are noteworthy. With a robust portfolio of patents and collaboration with leading researchers, he continues to push the boundaries of science at The Scripps Research Institute. His work not only aids in the characterization of drug targets but also lays the groundwork for future pharmaceutical developments.